

## WuXi inks cancer biomarker service deal with US firm

26 May 2014 | News | By BioSpectrum Bureau



Singapore: US based Targos, clinical biomarker service provider has signed a collaboration deal with China's WuXi PharmaTech to support its bioanalytical work for pharmaceutical customers.

The collaboration will focus on the validation and analysis of clinical tissue biomarkers in cancer. Targos will also provide its internationally known training and education to support pathologists and histotechnologists in generating accurate, objective, and reproducible diagnostic results. By adding these new molecular pathology testing services from Targos, WuXi will provide customers with a comprehensive platform of services in soluble, cell, and tissue biomarkers.

"We are pleased to have found in WuXi a partner who shares our vision of offering customers the highest-quality biomarker services," said Dr Thomas Henkel, CEO, Targos.

"This agreement with Targos advances WuXi's mission of offering our customers the broadest range of capabilities to support their drug development," said Dr Ge Li, Chairman and CEO, WuXi PharmaTech.